Literature DB >> 23955079

Opportunities and hurdles in the treatment of BRCA1-related breast cancer.

R Drost1, J Jonkers1.   

Abstract

BRCA1 functions as a classical tumor suppressor in breast and ovarian cancer. While the role of BRCA1 in homology-directed repair of DNA double-strand breaks contributes to its tumor suppressive activity, it also renders BRCA1-deficient cells highly sensitive to DNA-damaging agents. Although BRCA1 deficiency is therefore considered to be an attractive therapeutic target, re-activation of BRCA1 by secondary mutations has been shown to cause therapy resistance. In this review, we will assess the role of BRCA1 in both hereditary and sporadic breast cancer and discuss how different functionalities of the BRCA1 protein can contribute to its tumor suppressor function. In addition, we will discuss how this knowledge on BRCA1 function can help to overcome the hurdles encountered in the clinic and improve current treatment strategies for patients with BRCA1-related breast cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23955079     DOI: 10.1038/onc.2013.329

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

Review 1.  Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.

Authors:  H Wu; X Wu; Z Liang
Journal:  Gene Ther       Date:  2017-08-03       Impact factor: 5.250

2.  Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.

Authors:  Tereza Vaclová; Nicholas T Woods; Diego Megías; Sergio Gomez-Lopez; Fernando Setién; José María García Bueno; José Antonio Macías; Alicia Barroso; Miguel Urioste; Manel Esteller; Alvaro N A Monteiro; Javier Benítez; Ana Osorio
Journal:  Hum Mol Genet       Date:  2016-12-15       Impact factor: 6.150

3.  Mutational landscape of the essential autophagy gene BECN1 in human cancers.

Authors:  Saurabh V Laddha; Shridar Ganesan; Chang S Chan; Eileen White
Journal:  Mol Cancer Res       Date:  2014-01-29       Impact factor: 5.852

Review 4.  Emerging therapeutic targets in metastatic progression: A focus on breast cancer.

Authors:  Zhuo Li; Yibin Kang
Journal:  Pharmacol Ther       Date:  2016-03-19       Impact factor: 12.310

5.  BBIT20 inhibits homologous DNA repair with disruption of the BRCA1-BARD1 interaction in breast and ovarian cancer.

Authors:  Liliana Raimundo; Angela Paterna; Juliana Calheiros; Joana Ribeiro; David S P Cardoso; Ilaria Piga; Susana Junqueira Neto; Denise Hegan; Peter M Glazer; Stefano Indraccolo; Silva Mulhovo; José Luís Costa; Maria-José U Ferreira; Lucília Saraiva
Journal:  Br J Pharmacol       Date:  2021-06-11       Impact factor: 9.473

6.  BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells.

Authors:  J Xu; A Footman; Y Qin; K Aysola; S Black; V Reddy; K Singh; W Grizzle; S You; D Moellering; E S Reddy; Y Fu; V N Rao
Journal:  Int J Chronic Dis Ther       Date:  2016-06-23

7.  Expression of miR-146a-5p in breast cancer and its role in proliferation of breast cancer cells.

Authors:  Wei Gao; Jing Hua; Zhaoyang Jia; Jiping Ding; Zengwei Han; Yun Dong; Qing Lin; Yuan Yao
Journal:  Oncol Lett       Date:  2018-04-26       Impact factor: 2.967

8.  MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.

Authors:  Nerea Matamala; Maria Teresa Vargas; Ricardo González-Cámpora; Jose Ignacio Arias; Primitiva Menéndez; Eduardo Andrés-León; Kira Yanowsky; Ana Llaneza-Folgueras; Rebeca Miñambres; Beatriz Martínez-Delgado; Javier Benítez
Journal:  Oncotarget       Date:  2016-04-12

9.  PARP Inhibition by Flavonoids Induced Selective Cell Killing to BRCA2-Deficient Cells.

Authors:  Cathy Su; Alexis H Haskins; Chisato Omata; Yasushi Aizawa; Takamitsu A Kato
Journal:  Pharmaceuticals (Basel)       Date:  2017-10-12

10.  PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors.

Authors:  Feng Bai; Shiqin Liu; Xiong Liu; Daniel P Hollern; Alexandria Scott; Chuying Wang; Lihan Zhang; Cheng Fan; Li Fu; Charles M Perou; Wei-Guo Zhu; Xin-Hai Pei
Journal:  Breast Cancer Res       Date:  2021-01-21       Impact factor: 6.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.